Management Team Strengthening - Biodexa Pharmaceuticals PLC appointed Dr Gary A Shangold as Chief Medical Officer effective immediately [2] - Dr Shangold brings extensive experience across all phases of drug development in multiple therapeutic areas [4] - He previously served as Chief Medical Officer at Enteris BioPharma and Xanodyne Pharmaceuticals, and as CEO of NovaDel Pharma [4] - Dr Shangold holds an MD from Columbia University and completed residency and fellowship programs in Obstetrics & Gynecology and Reproductive Endocrinology [5] - He has approximately 10 years of experience in clinical and regulatory affairs at Johnson & Johnson's R W Johnson Pharmaceutical Research Institute [5] Company Overview - Biodexa is a clinical-stage biopharmaceutical company developing innovative products for diseases with unmet medical needs [8] - The company's lead development programs include eRapa for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer, tolimidone for type 1 diabetes, and MTX110 for aggressive rare/orphan brain cancers [8] - Biodexa utilizes three proprietary drug delivery technologies to improve bio-delivery and bio-distribution of medicines [12] - The company is headquartered in Cardiff, UK with an R&D facility [12] Product Pipeline - eRapa is an oral tablet formulation of rapamycin, an mTOR inhibitor that regulates cellular metabolism, growth, and proliferation [9] - Tolimidone is an oral Lyn kinase inhibitor that demonstrates glycemic control via insulin sensitization in animal models of diabetes [10] - MTX110 is a solubilized formulation of panobinostat, delivered via convection-enhanced delivery directly to tumor sites, bypassing the blood-brain barrier [11][12] Leadership Commentary - CEO Stephen Stamp emphasized the importance of Dr Shangold's expertise as Biodexa advances to later clinical stages, including a global Phase 3 registrational study in FAP [3] - Dr Shangold's previous experience includes securing two NDAs at Xanodyne Pharmaceuticals [3]
Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer